Previous studies have shown that IDH-1/2 mutated cholangiocarcinoma displays increased evidence of DNA damage, making POLY-ADP Ribose Polymerase (PARP) inhibitors a potential therapeutic option [31]. This evidence concerns the gene IDH1 and cholangiocarcinoma.